TY - JOUR
T1 - The Australian Diagnostic Criteria for Contrast-Induced Encephalopathy
AU - Mariajoseph, Frederick P.
AU - Lai, Leon T.
AU - Praeger, Adrian
AU - Chandra, Ronil V.
AU - Moore, Justin
AU - Asadi, Hamed
AU - de Villiers, Laetitia
AU - Goldschlager, Tony
AU - Gan, Calvin
AU - Zhou, Kevin
AU - Chiu, Albert Ho Yuen
AU - Miteff, Ferdinand
AU - Banez, Ramon Martin
AU - Phan, Thanh
AU - Pavlin-Premrl, Davor
AU - Chong, Winston
AU - Dunkerton, Sophie
AU - Madan, Anoop
AU - Slater, Lee Anne
N1 - Publisher Copyright:
© The Author(s) 2025.
PY - 2025/3/29
Y1 - 2025/3/29
N2 - Introduction: Contrast-induced encephalopathy (CIE) is a recognised complication of contrast administration, however diagnosis remains challenging due to its symptom overlap with other neurological conditions and the absence of formal diagnostic criteria. Methods: A modified Delphi study was performed. Consultant physicians with active clinical experience with CIE patients were invited from neurovascular centres in Australia. Initial diagnostic items were derived from an extensive literature review and analysis of local institutional cases across Australia. Three Delphi rounds were conducted. Consensus was defined as ≥ 75% agreement. Results: Seventeen neurovascular specialists from nine neurovascular centres participated (81.0% response rate) between May 2024 and July 2024. In round 1, 15 diagnostic items were presented to participants, which were revised and one additional criteria suggested. In round 2, 14/16 diagnostic items achieved consensus. In round three 14/14 items achieved consensus. Ultimately, a 14-item diagnostic criteria was developed based on participant consensus. The absolute criteria exclude CIE if symptom onset is more than 24 h after contrast administration, or if symptoms can be explained by vessel occlusion/territory ischaemia, intracranial haemorrhage, epilepsy, metabolic derangement, intracranial malignancy or head trauma. The supporting criteria indicate that CIE is more probable if symptoms are reversible, correspond with the distribution of contrast administration, or are associated with reversible contrast staining, cerebral oedema or cortical/subcortical MRI signal change. Conclusion: This study proposes a 14-item diagnostic criteria for CIE based on expert consensus in Australia. Further research is needed to refine CIE as a clinical entity.
AB - Introduction: Contrast-induced encephalopathy (CIE) is a recognised complication of contrast administration, however diagnosis remains challenging due to its symptom overlap with other neurological conditions and the absence of formal diagnostic criteria. Methods: A modified Delphi study was performed. Consultant physicians with active clinical experience with CIE patients were invited from neurovascular centres in Australia. Initial diagnostic items were derived from an extensive literature review and analysis of local institutional cases across Australia. Three Delphi rounds were conducted. Consensus was defined as ≥ 75% agreement. Results: Seventeen neurovascular specialists from nine neurovascular centres participated (81.0% response rate) between May 2024 and July 2024. In round 1, 15 diagnostic items were presented to participants, which were revised and one additional criteria suggested. In round 2, 14/16 diagnostic items achieved consensus. In round three 14/14 items achieved consensus. Ultimately, a 14-item diagnostic criteria was developed based on participant consensus. The absolute criteria exclude CIE if symptom onset is more than 24 h after contrast administration, or if symptoms can be explained by vessel occlusion/territory ischaemia, intracranial haemorrhage, epilepsy, metabolic derangement, intracranial malignancy or head trauma. The supporting criteria indicate that CIE is more probable if symptoms are reversible, correspond with the distribution of contrast administration, or are associated with reversible contrast staining, cerebral oedema or cortical/subcortical MRI signal change. Conclusion: This study proposes a 14-item diagnostic criteria for CIE based on expert consensus in Australia. Further research is needed to refine CIE as a clinical entity.
KW - Adverse event
KW - Complication
KW - Contrast
KW - Diagnosis
KW - Encephalopathy
KW - Endovascular
KW - Neurotoxicity
UR - http://www.scopus.com/inward/record.url?scp=105001476553&partnerID=8YFLogxK
U2 - 10.1007/s00234-025-03601-5
DO - 10.1007/s00234-025-03601-5
M3 - Article
C2 - 40156770
AN - SCOPUS:105001476553
SN - 0028-3940
JO - Neuroradiology
JF - Neuroradiology
ER -